Evoke Pharma Past Earnings Performance
Past criteria checks 0/6
Evoke Pharma has been growing earnings at an average annual rate of 5%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 67.5% per year.
Key information
5.0%
Earnings growth rate
22.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 67.5% |
| Return on equity | -245.0% |
| Net Margin | -86.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Evoke Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 8 | -7 | 13 | 0 |
| 31 Mar 24 | 6 | -7 | 13 | 0 |
| 31 Dec 23 | 5 | -8 | 12 | 0 |
| 30 Sep 23 | 4 | -8 | 11 | 0 |
| 30 Jun 23 | 4 | -8 | 11 | 0 |
| 31 Mar 23 | 3 | -8 | 10 | 0 |
| 31 Dec 22 | 3 | -8 | 10 | 0 |
| 30 Sep 22 | 2 | -8 | 9 | 0 |
| 30 Jun 22 | 2 | -8 | 9 | 0 |
| 31 Mar 22 | 2 | -8 | 9 | 0 |
| 31 Dec 21 | 2 | -9 | 9 | 1 |
| 30 Sep 21 | 1 | -9 | 9 | 1 |
| 30 Jun 21 | 0 | -9 | 8 | 1 |
| 31 Mar 21 | 0 | -14 | 7 | 6 |
| 31 Dec 20 | 0 | -13 | 6 | 7 |
| 30 Sep 20 | 0 | -12 | 5 | 7 |
| 30 Jun 20 | 0 | -12 | 4 | 8 |
| 31 Mar 20 | 0 | -7 | 4 | 3 |
| 31 Dec 19 | 0 | -7 | 4 | 3 |
| 30 Sep 19 | 0 | -7 | 4 | 3 |
| 30 Jun 19 | 0 | -7 | 4 | 3 |
| 31 Mar 19 | 0 | -8 | 4 | 3 |
| 31 Dec 18 | 0 | -8 | 4 | 4 |
| 30 Sep 18 | 0 | -6 | 4 | 5 |
| 30 Jun 18 | 0 | -10 | 4 | 7 |
| 31 Mar 18 | 0 | -9 | 4 | 8 |
| 31 Dec 17 | 0 | -12 | 4 | 7 |
| 30 Sep 17 | 0 | -13 | 4 | 7 |
| 30 Jun 17 | 0 | -11 | 4 | 6 |
| 31 Mar 17 | 0 | -13 | 4 | 6 |
| 31 Dec 16 | 0 | -11 | 4 | 7 |
| 30 Sep 16 | 0 | -12 | 4 | 7 |
| 30 Jun 16 | 0 | -12 | 4 | 8 |
| 31 Mar 16 | 0 | -12 | 4 | 8 |
| 31 Dec 15 | 0 | -12 | 4 | 8 |
| 30 Sep 15 | 0 | -12 | 4 | 9 |
| 30 Jun 15 | 0 | -14 | 3 | 10 |
| 31 Mar 15 | 0 | -14 | 3 | 11 |
| 31 Dec 14 | 0 | -13 | 3 | 10 |
| 30 Sep 14 | 0 | -12 | 3 | 8 |
| 30 Jun 14 | 0 | -9 | 3 | 5 |
| 31 Mar 14 | 0 | -5 | 2 | 3 |
Quality Earnings: EV0 is currently unprofitable.
Growing Profit Margin: EV0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EV0 is unprofitable, but has reduced losses over the past 5 years at a rate of 5% per year.
Accelerating Growth: Unable to compare EV0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EV0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: EV0 has a negative Return on Equity (-244.97%), as it is currently unprofitable.